Skip to Content


In the US, Actemra (tocilizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Cytokine Release Syndrome, Giant Cell Arteritis, Juvenile Idiopathic Arthritis and Rheumatoid Arthritis.

US matches:

Ingredient matches for Actemra


Tocilizumab is reported as an ingredient of Actemra in the following countries:

  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Azerbaijan
  • Belarus
  • Bosnia & Herzegowina
  • Canada
  • Chile
  • Ecuador
  • Georgia
  • Hong Kong
  • Indonesia
  • Israel
  • Japan
  • Kyrgyzstan
  • Macedonia
  • Malaysia
  • Moldova
  • Myanmar
  • Netherlands Antilles
  • New Zealand
  • Paraguay
  • Peru
  • Philippines
  • Russian Federation
  • Serbia
  • South Africa
  • Thailand
  • Turkey
  • Turkmenistan
  • United States
  • Uruguay
  • Vietnam

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.